EUTRIGTREAT
Identification and therapeutic targeting of common arrhythmia trigger mechanisms
| Coordinatore | UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.eutrigtreat.eu |
| Totale costo | 16˙027˙880 € |
| EC contributo | 12˙000˙000 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-IP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-10-01 - 2015-03-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS
Organization address
address: Robert-Koch-Strasse 40 contact info |
DE (GOETTINGEN) | coordinator | 2˙998˙140.00 |
| 2 | Endotherm GmbH | DE | participant | 900˙000.00 |
| 3 | POLYGENE AG | CH | participant | 900˙000.00 |
| 4 |
JOHANN WOLFGANG GOETHE UNIVERSITAET FRANKFURT AM MAIN
Organization address
address: GRUNEBURGPLATZ 1 contact info |
DE (FRANKFURT AM MAIN) | participant | 757˙100.00 |
| 5 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 719˙500.00 |
| 6 |
LIGHT4TECH FIRENZE SRL
Organization address
address: Via Pisana 316 contact info |
IT (SCANDICCI) | participant | 714˙000.00 |
| 7 |
"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"
Organization address
address: Soranou Efesiou 4 contact info |
EL (ATHENS) | participant | 700˙000.00 |
| 8 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 660˙600.00 |
| 9 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 620˙000.00 |
| 10 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 620˙000.00 |
| 11 |
UNIVERSITA DEGLI STUDI DI PADOVA
Organization address
address: VIA 8 FEBBRAIO 2 contact info |
IT (PADOVA) | participant | 600˙700.00 |
| 12 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 580˙300.00 |
| 13 |
University System of Maryland
Organization address
address: Metzerott Road 3300 contact info |
US (Adelphi) | participant | 523˙660.00 |
| 14 |
UNIVERSITAET BERN
Organization address
address: Hochschulstrasse 4 contact info |
CH (BERN) | participant | 520˙000.00 |
| 15 |
UNIVERSITA DEGLI STUDI DI FIRENZE
Organization address
address: Piazza San Marco 4 contact info |
IT (Florence) | participant | 186˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Arrhythmias are common manifestations of heart disease which frequently cause sudden cardiac death (SCD) or other devastating health problems. In Europe, prevention of SCD by device and drug therapy is expensive and increasingly strains public health resources due to a growing population at risk. However, identification of patients at increased risk for SCD is ineffective, and SCD prevention strategies are not directed at the underlying risk mechanisms. To address this challenging situation, new insights into genetic and environmental modulators of SCD risk, arrhythmia initiating mechanisms (Triggers) and therapeutic strategies (Treatments) are urgently needed. The EUTrigTreat consortium proposes a translational project strategy based on interactive objectives (modules). Module 1 investigates novel genetic arrhythmia mechanisms in patients and is supported by Module 2 which investigates genetic and environmental SCD risk modulators in animals with arrhythmias. Module 3 elucidates common environmental arrhythmia risk mediators including obesity and diabetes. Module 4 applies molecular and biophysical imaging techniques to identify novel risk biomarkers. Module 5 translates experimental data through computer modeling and prediction analysis. Modules 6 develops new SCD risk identification strategies through combined patient and experimental studies. Module 7 develops and validates novel therapeutic drug compounds and a new form of anti-arrhythmic device therapy. The pre-clinical and clinical activities will potentially result in patents of diagnostic and therapeutic applications, licensing strategies, early clinical trials and a spin-off company. Module 8 manages, advises and reviews the project progress of EUTrigTreat. Ultimately, we aim to better understand and educate about arrhythmia initiating mechanisms and associated risk biomarkers. Such knowledge will provide strong rationales towards improved prevention and treatment of patients at risk for SCD.'